β-catenin  ||| S:0 E:10 ||| NNP
is  ||| S:10 E:13 ||| VBZ
regulated  ||| S:13 E:23 ||| VBN
by  ||| S:23 E:26 ||| IN
USP9x  ||| S:26 E:32 ||| NNP
and  ||| S:32 E:36 ||| CC
mediates  ||| S:36 E:45 ||| JJ
resistance  ||| S:45 E:56 ||| NN
to  ||| S:56 E:59 ||| TO
TRAIL-induced  ||| S:59 E:73 ||| JJ
apoptosis  ||| S:73 E:83 ||| NN
in  ||| S:83 E:86 ||| IN
breast  ||| S:86 E:93 ||| JJ
cancer  ||| S:93 E:100 ||| NN
To  ||| S:100 E:103 ||| TO
investigate  ||| S:103 E:115 ||| VB
the  ||| S:115 E:119 ||| DT
regulatory  ||| S:119 E:130 ||| JJ
mechanisms  ||| S:130 E:141 ||| NNS
of  ||| S:141 E:144 ||| IN
decoy  ||| S:144 E:150 ||| JJ
receptor  ||| S:150 E:159 ||| NN
expression  ||| S:159 E:170 ||| NN
in  ||| S:170 E:173 ||| IN
TRAIL-resistant  ||| S:173 E:189 ||| JJ
breast  ||| S:189 E:196 ||| NN
cancer  ||| S:196 E:203 ||| NN
MCF-7  ||| S:203 E:209 ||| CD
cells ||| S:209 E:214 ||| NNS
,  ||| S:214 E:216 ||| ,
cytotoxicity  ||| S:216 E:229 ||| NN
and  ||| S:229 E:233 ||| CC
apoptosis  ||| S:233 E:243 ||| JJ
assays  ||| S:243 E:250 ||| NN
were  ||| S:250 E:255 ||| VBD
applied  ||| S:255 E:263 ||| VBN
to  ||| S:263 E:266 ||| TO
examine  ||| S:266 E:274 ||| VB
sensitivity  ||| S:274 E:286 ||| VBN
to  ||| S:286 E:289 ||| TO
TRAIL  ||| S:289 E:295 ||| NNP
in  ||| S:295 E:298 ||| IN
breast  ||| S:298 E:305 ||| JJ
cancer  ||| S:305 E:312 ||| NN
cells ||| S:312 E:317 ||| NNS
.  ||| S:317 E:319 ||| .
Immunofluorescence  ||| S:319 E:338 ||| NNP
and  ||| S:338 E:342 ||| CC
immunoprecipitation  ||| S:342 E:362 ||| NNS
were  ||| S:362 E:367 ||| VBD
used  ||| S:367 E:372 ||| VBN
to  ||| S:372 E:375 ||| TO
detect  ||| S:375 E:382 ||| VB
the  ||| S:382 E:386 ||| DT
co-localization  ||| S:386 E:402 ||| JJ
and  ||| S:402 E:406 ||| CC
interaction  ||| S:406 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
USP9x  ||| S:421 E:427 ||| NNP
and  ||| S:427 E:431 ||| CC
β-catenin ||| S:431 E:440 ||| JJ
.  ||| S:440 E:442 ||| .
Luciferase  ||| S:442 E:453 ||| JJ
assay  ||| S:453 E:459 ||| NN
was  ||| S:459 E:463 ||| VBD
used  ||| S:463 E:468 ||| VBN
to  ||| S:468 E:471 ||| TO
examine  ||| S:471 E:479 ||| VB
activity  ||| S:479 E:488 ||| NN
of  ||| S:488 E:491 ||| IN
the  ||| S:491 E:495 ||| DT
DcR1 ||| S:495 E:499 ||| NNP
/ ||| S:499 E:500 ||| NNP
DcR2 ||| S:500 E:504 ||| NNP
/ ||| S:504 E:505 ||| NNP
OPG  ||| S:505 E:509 ||| NNP
reporter ||| S:509 E:517 ||| NN
.  ||| S:517 E:519 ||| .
Overexpression ||| S:519 E:533 ||| NNP
/ ||| S:533 E:534 ||| NNP
silencing  ||| S:534 E:544 ||| NN
of  ||| S:544 E:547 ||| IN
β-catenin  ||| S:547 E:557 ||| NNP
was  ||| S:557 E:561 ||| VBD
performed  ||| S:561 E:571 ||| VBN
to  ||| S:571 E:574 ||| TO
confirm  ||| S:574 E:582 ||| VB
β-catenin  ||| S:582 E:592 ||| JJ
mediated  ||| S:592 E:601 ||| JJ
transcription  ||| S:601 E:615 ||| NN
of  ||| S:615 E:618 ||| IN
the  ||| S:618 E:622 ||| DT
decoy  ||| S:622 E:628 ||| JJ
receptors ||| S:628 E:637 ||| NNS
.  ||| S:637 E:639 ||| .
Additionally ||| S:639 E:651 ||| RB
,  ||| S:651 E:653 ||| ,
silencing  ||| S:653 E:663 ||| VBG
of  ||| S:663 E:666 ||| IN
USP9x  ||| S:666 E:672 ||| NNP
was  ||| S:672 E:676 ||| VBD
performed  ||| S:676 E:686 ||| VBN
to  ||| S:686 E:689 ||| TO
prove  ||| S:689 E:695 ||| VB
that  ||| S:695 E:700 ||| IN
USP9X  ||| S:700 E:706 ||| NNP
stabilizes  ||| S:706 E:717 ||| VBZ
β-catenin  ||| S:717 E:727 ||| JJ
and  ||| S:727 E:731 ||| CC
mediates  ||| S:731 E:740 ||| JJ
TRAIL-resistance ||| S:740 E:756 ||| NN
.  ||| S:756 E:758 ||| .
It  ||| S:758 E:761 ||| PRP
was  ||| S:761 E:765 ||| VBD
found  ||| S:765 E:771 ||| VBN
that  ||| S:771 E:776 ||| IN
USP9x  ||| S:776 E:782 ||| CD
interacted  ||| S:782 E:793 ||| NN
with  ||| S:793 E:798 ||| IN
β-catenin  ||| S:798 E:808 ||| JJ
and  ||| S:808 E:812 ||| CC
inhibited  ||| S:812 E:822 ||| VBD
the  ||| S:822 E:826 ||| DT
degradation  ||| S:826 E:838 ||| NN
of  ||| S:838 E:841 ||| IN
β-catenin  ||| S:841 E:851 ||| JJ
through  ||| S:851 E:859 ||| IN
the  ||| S:859 E:863 ||| DT
deubiquitination  ||| S:863 E:880 ||| NN
of  ||| S:880 E:883 ||| IN
β-catenin ||| S:883 E:892 ||| JJ
.  ||| S:892 E:894 ||| .
Luciferase  ||| S:894 E:905 ||| JJ
reporter  ||| S:905 E:914 ||| NN
assays  ||| S:914 E:921 ||| NNS
showed  ||| S:921 E:928 ||| VBD
induction  ||| S:928 E:938 ||| VBN
of  ||| S:938 E:941 ||| IN
DcR1 ||| S:941 E:945 ||| NNP
/ ||| S:945 E:946 ||| NNP
DcR2 ||| S:946 E:950 ||| NNP
/ ||| S:950 E:951 ||| NNP
OPG  ||| S:951 E:955 ||| NNP
reporter  ||| S:955 E:964 ||| NN
activity  ||| S:964 E:973 ||| NN
observed  ||| S:973 E:982 ||| VBD
upon  ||| S:982 E:987 ||| IN
co-transfection  ||| S:987 E:1003 ||| JJ
of  ||| S:1003 E:1006 ||| IN
β-catenin  ||| S:1006 E:1016 ||| JJ
and  ||| S:1016 E:1020 ||| CC
Tcf-4 ||| S:1020 E:1025 ||| NNP
.  ||| S:1025 E:1027 ||| .
The  ||| S:1027 E:1031 ||| DT
overexpression ||| S:1031 E:1045 ||| JJ
/ ||| S:1045 E:1046 ||| CD
silencing  ||| S:1046 E:1056 ||| NN
of  ||| S:1056 E:1059 ||| IN
β-catenin  ||| S:1059 E:1069 ||| JJ
further  ||| S:1069 E:1077 ||| RB
confirmed  ||| S:1077 E:1087 ||| VBD
the  ||| S:1087 E:1091 ||| DT
role  ||| S:1091 E:1096 ||| NN
of  ||| S:1096 E:1099 ||| IN
β-catenin  ||| S:1099 E:1109 ||| JJ
in  ||| S:1109 E:1112 ||| IN
the  ||| S:1112 E:1116 ||| DT
regulation  ||| S:1116 E:1127 ||| NN
of  ||| S:1127 E:1130 ||| IN
transcription  ||| S:1130 E:1144 ||| NN
of  ||| S:1144 E:1147 ||| IN
the  ||| S:1147 E:1151 ||| DT
decoy  ||| S:1151 E:1157 ||| JJ
receptors ||| S:1157 E:1166 ||| NNS
.  ||| S:1166 E:1168 ||| .
Silencing  ||| S:1168 E:1178 ||| NNP
of  ||| S:1178 E:1181 ||| IN
USP9x  ||| S:1181 E:1187 ||| NNP
directly  ||| S:1187 E:1196 ||| RB
evidenced  ||| S:1196 E:1206 ||| VBN
that  ||| S:1206 E:1211 ||| IN
USP9x  ||| S:1211 E:1217 ||| NNP
affected  ||| S:1217 E:1226 ||| VBD
the  ||| S:1226 E:1230 ||| DT
protein  ||| S:1230 E:1238 ||| NN
expression  ||| S:1238 E:1249 ||| NN
level  ||| S:1249 E:1255 ||| NN
of  ||| S:1255 E:1258 ||| IN
β-catenin ||| S:1258 E:1267 ||| NNP
,  ||| S:1267 E:1269 ||| ,
the  ||| S:1269 E:1273 ||| DT
transcription  ||| S:1273 E:1287 ||| JJ
level  ||| S:1287 E:1293 ||| NN
of  ||| S:1293 E:1296 ||| IN
the  ||| S:1296 E:1300 ||| DT
decoy  ||| S:1300 E:1306 ||| JJ
receptors ||| S:1306 E:1315 ||| NNS
,  ||| S:1315 E:1317 ||| ,
and  ||| S:1317 E:1321 ||| CC
reversed  ||| S:1321 E:1330 ||| VBD
TRAIL-resistance  ||| S:1330 E:1347 ||| JJ
of  ||| S:1347 E:1350 ||| IN
MCF-7  ||| S:1350 E:1356 ||| CD
cells ||| S:1356 E:1361 ||| NNS
.  ||| S:1361 E:1363 ||| .
In  ||| S:1363 E:1366 ||| IN
conclusion ||| S:1366 E:1376 ||| NN
,  ||| S:1376 E:1378 ||| ,
USP9x  ||| S:1378 E:1384 ||| CD
interacted  ||| S:1384 E:1395 ||| NN
with  ||| S:1395 E:1400 ||| IN
and  ||| S:1400 E:1404 ||| CC
stabilized  ||| S:1404 E:1415 ||| VBD
β-catenin  ||| S:1415 E:1425 ||| JJ
through  ||| S:1425 E:1433 ||| IN
deubiquitination  ||| S:1433 E:1450 ||| VBG
to  ||| S:1450 E:1453 ||| TO
mediate  ||| S:1453 E:1461 ||| VB
transcription  ||| S:1461 E:1475 ||| VBN
of  ||| S:1475 E:1478 ||| IN
the  ||| S:1478 E:1482 ||| DT
decoy  ||| S:1482 E:1488 ||| JJ
receptors  ||| S:1488 E:1498 ||| NNS
in  ||| S:1498 E:1501 ||| IN
breast  ||| S:1501 E:1508 ||| JJ
cancer  ||| S:1508 E:1515 ||| NN
cells ||| S:1515 E:1520 ||| NNS
.  ||| S:1520 E:1522 ||| .
Our  ||| S:1522 E:1526 ||| PRP$
results  ||| S:1526 E:1534 ||| NNS
offer  ||| S:1534 E:1540 ||| VBP
new  ||| S:1540 E:1544 ||| JJ
insights  ||| S:1544 E:1553 ||| NNS
into  ||| S:1553 E:1558 ||| IN
the  ||| S:1558 E:1562 ||| DT
mechanisms  ||| S:1562 E:1573 ||| NNS
of  ||| S:1573 E:1576 ||| IN
resistance  ||| S:1576 E:1587 ||| NN
to  ||| S:1587 E:1590 ||| TO
TRAIL ||| S:1590 E:1595 ||| NNP
,  ||| S:1595 E:1597 ||| ,
and  ||| S:1597 E:1601 ||| CC
USP9x  ||| S:1601 E:1607 ||| NNP
could  ||| S:1607 E:1613 ||| MD
potentially  ||| S:1613 E:1625 ||| RB
be  ||| S:1625 E:1628 ||| VB
a  ||| S:1628 E:1630 ||| DT
therapeutic  ||| S:1630 E:1642 ||| JJ
target  ||| S:1642 E:1649 ||| NN
for  ||| S:1649 E:1653 ||| IN
TRAIL-resistant  ||| S:1653 E:1669 ||| JJ
breast  ||| S:1669 E:1676 ||| NN
cancers ||| S:1676 E:1683 ||| NNS
.  ||| S:1683 E:1685 ||| .
